Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perspectives of people with HIV on implementing long acting cabotegravir plus rilpivirine in clinics and community settings in the UK: results from the anti-sexist, anti-racist, anti-ageist ILANA study.
Orkin C, Hayes R, Haviland J, Wong YL, Ring K, Apea V, Kasadha B, Clarke E, Byrne R, Fox J, Barber TJ, Clarke A, Paparini S; ILANA study Group. Orkin C, et al. Clin Infect Dis. 2024 Oct 28:ciae523. doi: 10.1093/cid/ciae523. Online ahead of print. Clin Infect Dis. 2024. PMID: 39465685
Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design.
Farooq HZ, Apea V, Kasadha B, Ullah S, Hilton-Smith G, Haley A, Scherzer J, Hand J, Paparini S, Phillips R, Orkin CM. Farooq HZ, et al. BMJ Open. 2023 Jul 9;13(7):e070666. doi: 10.1136/bmjopen-2022-070666. BMJ Open. 2023. PMID: 37423623 Free PMC article.
Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
Ring K, Smuk M, Shongwe M, Okonta L, Mackie NE, Ayres S, Barber TJ, Akodu J, Ferro F, Chilton D, Hurn E, Halai B, Barchi W, Ali A, Darko S, White G, Clarke E, Clark F, Ali B, Arumainayagam J, Quinn G, Boffito M, Byrne R, Naous N, Leung S, Umaipalan A, Thornton B, Bayliss D, McLoughlin C, Foster J, Waters L, Orkin C. Ring K, et al. Among authors: orkin c. HIV Med. 2024 Oct;25(10):1125-1134. doi: 10.1111/hiv.13679. Epub 2024 Jun 10. HIV Med. 2024. PMID: 38858222
Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?
Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ, Mahungu T, Ferro F, Sood C, Freeman C, Phillips C, Dhairyawan R, Burholt R, Sharp H, Ullah S, Gilleece Y, Brown A, Orkin C, Rodger A, Bhagani S. Garvey LJ, et al. Among authors: orkin c. Clin Infect Dis. 2021 Jan 27;72(2):233-238. doi: 10.1093/cid/ciaa021. Clin Infect Dis. 2021. PMID: 32211763 Free PMC article.
International Women's Day-how can I help?
Orkin C, Apea V. Orkin C, et al. Lancet HIV. 2022 Apr;9(4):e228-e229. doi: 10.1016/S2352-3018(22)00060-1. Epub 2022 Mar 7. Lancet HIV. 2022. PMID: 35271826 No abstract available.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
SHARING to create knowledge in a crisis.
Orkin C, Paparini S, Thornhill JP, Apea V, Mwendera CA, Smuk M, Hayes R, Anderson J; SHARE Collaborative. Orkin C, et al. BMJ Lead. 2023 Aug;7(Suppl 2):e000810. doi: 10.1136/leader-2023-000810. BMJ Lead. 2023. PMID: 37591607 No abstract available.
351 results